The biotechnology industry from around the world discussed in Warsaw

The most important challenges for the development of the biotechnology market were the topic of the international conference Central European BioForum 2024 (CEBioForum 2024). This is the largest event in this industry in Poland, attended by over 400 participants representing companies and institutions in the biotechnology sector from Europe and North America.

“By organizing the conference, we want to show the increasing importance of the biotechnology sector and how it increasingly influences the economy in various areas,” said Dr. Magdalena Kulczycka, managing director of the Association of Biotechnology Companies BioForum, opening the forum.

The forum was attended by Deputy Minister of Development and Technology Jacek Tomczak, who pointed to the growing impact of biotechnology on the modernization of European industry in areas such as food, materials and medicines. “The European Commission also sees the sector’s potential and considers it crucial, which is expressed in its strategic goals for the development of the industry,” he emphasized. He informed that the Polish biotechnology sector is worth approximately PLN 2 billion.

The Polish biotechnology market includes over 200 companies and employs several thousand employees. Biotechnology is currently playing an increasingly important role in the development of medicine, agriculture, waste disposal and the implementation of sustainable development goals.

Gene therapies, commercialization and fundraising

The main topics of discussion at the forum, with the participation of the most important companies from the biotechnology sector, included: issues of the use of cell and genetic therapies in the treatment of diseases and the development of biotechnological innovations – from the stage of laboratory research to market entry. They also talked about raising funds for operations, challenges related to bioproduction and commercialization of research, preparing the company for clinical trials, as well as the specifics of entering the British and American markets, which are crucial for the BioTech industry.

Dr. Claire Skentelbery, director general of EuropaBio – the European Bio-Industry Association, emphasized that biotechnology, along with artificial intelligence and quantum and chip technology, is treated as a critical technology of the European economy in the current time of geopolitical tensions. She pointed to Poland’s important role during our country’s planned presidency of the Council of the European Union in 2025, especially in the context of regulations regarding the pharmaceutical market (General Pharmaceutical Legislation), biotechnology production (Bio&Biomanufacturing Initiative), as well as New Genomic Techniques (NGT) in agriculture.

There were also issues related to the creation of biotechnological innovations that can support patients with rare diseases or those that are currently incurable. The panel on this topic was attended by representatives of: Novartis Gene Therapy & Rare Diseases, Medical Research Agency, PolTREG, Wardyński & Partners law firm and ExecMind.

The discussion on the preparation of companies for clinical trials, which is important in the process of commercialization of biotechnological solutions, was attended by representatives of: Pfizer, Polpharma Biologics, Bioton and the Institute of Experimental Biology of the Polish Academy of Sciences. M. Nencki. The discussion focused on the development of innovations in such a way that the threshold of entering the market with them was as small and as cost-effective as possible.

The conference also discussed the financing of biotechnology companies, and in particular the conditions related to individual forms of financing – through capital fund investments, entering the stock exchange or financing operations with public aid, i.e. grants from government agencies. The advantages and disadvantages of each type of financing were discussed, which the panelists presented by sharing their experiences.

There was also a discussion about global trends in biotechnology and the possibilities and methods of expansion of Polish companies to the American and British markets, which are the markets of first choice for Polish biotech companies in foreign expansion. At the same time, the panel on entering the British market initiated a program that BioForum is implementing together with the British Ministry of Business and Trade and local partners.

CEBioForum Awards

As every year, CEBioForum Awards were presented during the event Gala. They were awarded to winners in four categories: the greatest impact on the development of the biotechnology sector in Poland (personal award), R&D Collaboration, Innovative Startup and Special Jury Award.

The award in the Innovative Startup category went to Biotreat Vascular sp. z o.o. It was appreciated for the implementation of an innovative biomaterial that improves the treatment of circulatory system ailments. The person with the greatest influence in the industry was chosen prof. Ph.D. Jacek Jemielity. He was appreciated for his many years of contribution to the development of technology that was commercialized and used in mRNA-based vaccines by a leading pharmaceutical company.

Acellmed sp. z o. o. received recognition in the R&D Collaboration category for creating a 3D-printed, personalized eye patch for corneal reconstruction. The Jury Award went to SDS Optic S.A. The company was recognized for its efforts in the development and commercialization on global markets of a Polish invention enabling quick and precise diagnosis of breast cancer along with modern therapy.

The organizer of the conference – the Association of Biotechnology Companies BioForum – represents over 30 largest entities in the biotechnology sector in Poland. The aim of the Association’s activities – as Robert Mikulski, president of the management board, says – is to integrate the sector and represent the interests of the industry. “We do this, among other things: by organizing international meetings during which people who create or intend to create companies related to biotechnology have the opportunity to directly exchange experiences,” he emphasizes. This year’s CEBioForum was the 22nd edition of the conference.

The event was held under the patronage of the Minister of Development and Technology and the President of the Capital City of Warsaw, Polish Investment and Trade Agency (PAIH) and Medical Research Agency.

CEBioForum 2024
in numbers


Over 450 participants from 21 countries took part in this year’s edition of CEBioForum.

We were visited by representatives of:
170 companies from the industry,
30 universities and scientific institutes as well
8 State Institutions.



See you during the next edition of CEBioForum

Join us and become a member of BioForum.

You can find more about our activities in the ASSOCIATION tab.